DATED AS OFInvestors' Rights Agreement • July 6th, 2007 • Constant Contact, Inc. • Delaware
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 5th, 2024 • ArriVent Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of December 16, 2022, by and among ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
AMYLYX PHARMACEUTICALS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT July 1, 2021Investors’ Rights Agreement • October 20th, 2021 • Amylyx Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 1st day of July, 2021 (the “Effective Date”) by and among AMYLYX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and any additional investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 22nd, 2021 • Braze, Inc. • Services-prepackaged software • Delaware
THIS FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 24th day of September, 2018, by and among Braze, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto and any person that becomes a party to this Agreement in accordance with Section 6.9 hereof), each of which is referred to in this Agreement as an “Investor.”
RECITALSInvestors' Rights Agreement • October 17th, 2007 • China Nepstar Chain Drugstore Ltd. • New York
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 14th, 2022 • Good Earth Organics, Inc. • Agricultural production-crops • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of January 7, 2022, by and among The Good Earth Organics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
OPTI-HARVEST, INC. INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • December 29th, 2023 • Opti-Harvest, Inc. • Farm machinery & equipment • Delaware
This Investors’ Rights Agreement (this “Agreement”) is made as of April ___, 2023, by and among Opti-Harvest, Inc., a Delaware corporation (the “Company”), and the persons and entities (each, an “Investor” and collectively, the “Investors”) listed on Exhibit A hereto. Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1.
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • February 14th, 2022 • Dynamics Special Purpose Corp. • Blank checks • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 22nd day of October, 2020, by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”) and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
THERACELL, INC. INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 2nd, 2022 • California
by and among Theracell, Inc., a Delaware corporation (the “Company”) and each of the persons and entities holding outstanding securities of the Company and executing a counterpart signature page to this Agreement (each, an “Investor” and collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 4.
SEQUOIA VACCINES, INC. 2021 INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 6th, 2023 • Sequoia Vaccines, Inc. • Biological products, (no disgnostic substances) • Missouri
THIS 2021 INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of ____April 30__, 2021 by and among Sequoia Vaccines, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A (each of which is referred to in this Agreement as an “Investor”), and any additional investor that becomes a party to this Agreement in accordance with Section 6.9 hereof. This Agreement supersedes and replaces in its entirety that 2020 Amended and Restated Investors’ Rights Agreement dated April 6, 2020 by and among the Company and the other parties thereto.
RECITALSInvestors' Rights Agreement • May 23rd, 2002 • Ashton Technology Group Inc • Services-computer programming services • New York
RECITALSInvestors' Rights Agreement • September 16th, 2003 • Cancervax Corp • Biological products, (no disgnostic substances) • California
NKARTA, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 27, 2019Investors’ Rights Agreement • June 19th, 2020 • Nkarta, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of August, 2019, by and among Nkarta, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees who become parties to this Agreement in accordance with Section 6.9 hereof, each an “Investor” and together the “Investors”).
SAMSARA NETWORKS INC. SEVENTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • November 19th, 2021 • Samsara Inc. • Services-computer integrated systems design • California
This Seventh Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of January 13, 2021 by and among Samsara Networks Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” any Additional Purchaser (as defined in that certain Extension Series F Preferred Stock Purchase Agreement, dated as of May 15, 2020, by and among the Company and certain of the Investors (the “Purchase Agreement”)) that becomes a party to this Agreement in accordance with Section 7.14 hereof and any holder of a Lender Warrant that becomes a party to this Agreement in accordance with Section 7.14 hereof.
INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 1st, 2023 • Life Spectacular, Inc. • Soap, detergents, cleang preparations, perfumes, cosmetics • Delaware
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of October 26, 2021 , by and among Life Spectacular, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder”.
RECITALSInvestors' Rights Agreement • July 16th, 2004 • Odimo INC • New York
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NEUMORA THERAPEUTICS, INC. September 22, 2022Investors’ Rights Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 22, 2022, by and among Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors in the Company’s Series B Preferred Stock (the “Series B Investors”), the investors in the Company’s Series A-2 Preferred Stock (the “Series A-2 Investors”), and the investors in the Company’s Series A-1 Preferred Stock (the “Series A-1 Investors,” together with the Series A-2 Investors, the “Series A Investors,” and together with the Series B Investors, the “Investors”) listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
ACCENTIA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 2nd, 2005 • Accentia Biopharmaceuticals Inc • Pharmaceutical preparations • Florida
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of January 7, 2005 by and among ACCENTIA BIOPHARMACEUTICALS, INC., a Florida corporation, having its principal place of business located at 5310 Cypress Center Drive, Suite 101, Tampa, FL 33609 (the “Company”), and Pharmaceutical Product Development, Inc., a North Carolina corporation, having its principal place of business located at 3151 South 17th Street, Wilmington, NC 28412 (“PPD”), and supersedes and replaces in its entirety that certain Investors’ Rights Agreement dated January 9, 2004 by and between the Company and PPD (the “Original Agreement”).
IRHYTHM TECHNOLOGIES, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT May 16, 2014Investors’ Rights Agreement • October 7th, 2016 • iRhythm Technologies, Inc. • Surgical & medical instruments & apparatus • California
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of May 16, 2014, by and among iRhythm Technologies, Inc., a Delaware corporation (the “Company”), and the persons and entities (each, an “Investor” and collectively, the “Investors”) listed on Exhibit A hereto. Unless otherwise defined herein, capitalized terms used in this Agreement have the meanings ascribed to them in Section 1.
AMENDMENT AND WAIVERInvestors' Rights Agreement • October 16th, 2001 • Acusphere Inc • Pharmaceutical preparations • Massachusetts
ALTO NEUROSCIENCE, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 12th, 2024 • Alto Neuroscience, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of November 20, 2023, by and among ALTO NEUROSCIENCE, INC., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
NEON THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT DECEMBER 28, 2016Investors’ Rights Agreement • May 31st, 2018 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 28, 2016, by and among Neon Therapeutics, Inc., a Delaware corporation (the “Company”), and each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor.”
AGREEMENT ---------Investor's Rights Agreement • November 1st, 2002 • Fibernet Telecom Group Inc\ • Telephone communications (no radiotelephone) • New York
RECITALSInvestors' Rights Agreement • June 1st, 2009 • Duoyuan Global Water Inc. • New York
OCCAM NETWORKS, INC. FOURTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • January 13th, 2005 • Occam Networks Inc/De • Computer communications equipment • California
This Fourth Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made and entered into as of January 7, 2005 by and among Occam Networks, Inc., a Delaware corporation (the “Company”); the undersigned purchasers (each, an “Investor” and collectively, the “Investors”) of the Company’s Series A Preferred Stock (as defined herein) originally issued pursuant to the Series A Preferred Stock Purchase Agreement dated as of December 19, 2002 (the “2002 Purchase Agreement”) and/or shares of the Company’s Series A-2 Preferred Stock (as defined herein) issued pursuant to the Series A-2 Preferred Stock Purchase Agreement (the “2003 Purchase Agreement”) dated as of November 19, 2003 as amended by Amendment No. 1 to Series A-2 Preferred Stock Purchase Agreement dated as of March 8, 2004 herewith (the “Amendment” and together with the 2003 Purchase Agreement, the “Amended Purchase Agreement”) and/or the Series A-2 Preferred Stock Purchase Agreement of even date herewith (the “2004 Pu
SHARE SUBSCRIPTION AGREEMENT between ECMOHO LIMITED, andInvestors Rights Agreement • September 26th, 2019 • ECMOHO LTD • Retail-catalog & mail-order houses • New York
THIS INVESTORS RIGHTS AGREEMENT (including the exhibits hereto, this “Agreement”), dated as of [●], 2018 (the “Execution Date”), is made by and among:
FIFTH AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT August 5, 2016Investors’ Rights Agreement • August 15th, 2018 • BioNano Genomics, Inc • Laboratory analytical instruments • Delaware
This will confirm that in consideration of the Series D-1 Investors’ agreement on the date hereof to purchase shares of Series D-1 Convertible Participating Preferred Stock, par value $0.0001 per share (the “Series D-1 Preferred Stock”), of BioNano Genomics, Inc., a Delaware corporation and successor to BioNanomatrix, LLC (the “Company”), pursuant to the Series D-1 Convertible Participating Preferred Stock Purchase Agreement of even date herewith (as the same may be amended from time to time, the “Purchase Agreement”) between the Company and the Series D-1 Investors and as an inducement to the Series D-1 Investors to consummate the transactions contemplated by the Purchase Agreement, the Company, the Series D-1 Investors and the other signatories hereto hereby agree as follows:
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT GOOD TECHNOLOGY CORPORATION MAY 3, 2014Investors’ Rights Agreement • May 23rd, 2014 • GOOD TECHNOLOGY Corp • Services-prepackaged software • California
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of the 3rd day of May, 2014, by and among Good Technology Corporation, a Delaware corporation (the “Company”) and the investors listed on Schedule A hereto (the “Investors”).
ContractInvestors’ Rights Agreement • May 5th, 2020 • Delaware
EX-4.1 3 ex-41secondamendedandresta.htm EXHIBIT 4.1 Execution Version Exhibit 4.1 SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of September 25th, 2019, by and among IMH Financial Corporation, a Delaware corporation (the “Company”), and each of the other Persons signatory hereto or that executes and delivers a joinder agreement pursuant to Section 8. Capitalized terms used but not otherwise defined herein are defined in Section 13. WHEREAS, the Company and SRE Monarch, LLC, a Delaware limited liability company (“SRE”), are parties to the Series B-2 Cumulative Convertible Preferred Stock Subscription Agreement dated as of July 23, 2014 (the “SRE Purchase Agreement”); WHEREAS, the Company, JCP Realty Partners, LLC, a Delaware limited liability company (“JCP Realty”), and Juniper NVM, LLC, a Delaware limited liability company (“Juniper NVM”), are parties to the Series B-1 Cumulative Conver
PULMONX CORPORATION AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • September 4th, 2020 • Pulmonx Corp • Surgical & medical instruments & apparatus • California
This Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of April 16, 2019 (the “Effective Date”), by and among Pulmonx Corporation, a Delaware corporation (the “Company”), the holders of the Company’s Series A‑1 Preferred Stock (the “Series A‑1 Preferred Stock”) set forth on Exhibit A hereto (the “Series A‑1 Holders”), the holders of the Company’s Series B‑1 Preferred Stock (the “Series B‑1 Preferred Stock”) set forth on Exhibit A hereto (the “Series B‑1 Holders”), the holders of the Company’s Series C‑1 Preferred Stock (the “Series C‑1 Preferred Stock”) set forth on Exhibit A hereto (the “Series C-1 Holders”), the holders of the Company’s Series D-1 Preferred Stock (the “Series D-1 Preferred Stock”) set forth on Exhibit A hereto (the “Series D‑1 Holders”), the holders of the Company’s Series E-1 Preferred Stock (the “Series E-1 Preferred Stock”) set forth on Exhibit A hereto (the “Series E‑1 Holders”), the holders of the Company’s Series F-1 Preferred Stock
VERTICALS ONDEMAND, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT May 16, 2008Investors’ Rights Agreement • September 11th, 2013 • Veeva Systems Inc • Services-prepackaged software • California
THIS INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of the 16th day of May, 2008, by and among VERTICALS ONDEMAND, INC., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto, each of which is herein referred to as an “Investor.”
SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 1st, 2021 • Caribou Biosciences, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of March 2, 2021, by and among Caribou Biosciences, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (each, an “Investor”) and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
EXHIBIT 10.23 AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT This Agreement is made as of January 23, 2001 by and among TheraSense, Inc., a Delaware corporation (the "Company"), and the holders of the Company's Preferred Stock, set forth on Exhibit A...Investors Rights Agreement • July 3rd, 2001 • Therasense Inc • Surgical & medical instruments & apparatus • California
AMENDED & RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • April 28th, 2023 • Gin & Luck Inc. • Retail-eating & drinking places • Delaware
THIS AMENDED & RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 19th day of August, 2021 by and among Gin & Luck Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto (together with any subsequent investors, or transferees, who become parties hereto, the “Investors”), and the holders of Common Stock (defined below) listed on Schedule B hereto (each of which is referred to in this Agreement as a “Common Holder”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT BOUNDLESS BIO, INC. April 5, 2023Investors’ Rights Agreement • September 1st, 2023 • Boundless Bio, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of April 5, 2023, by and among Boundless Bio, Inc. a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
